This delay in achieving clinical response to oncolytic viruses is notably similar to the literature describing delayed clinical responses to PD-1/PD-L1 immune checkpoint blockade in patients with melanoma and non-small cell lung cancer, with a clear benefit of continuing therapy even beyond clinical progression [77,78,79,80]. Here, PDCD1 is linked to non-small cell lung carcinoma.